NBC Journalist Diagnosed with T-cell Lymphoma
Mike Celizic, a contributing sports columnist for NBCsports.com and journalist for Todayshow.com and msnbc.com, was recently diagnosed with T-cell lymphoma, and in response he's done what you might expect of a journalist—he's reporting on it, in the form of a compelling blog titled "Adventures in Cancerland"
Celizic (at right, pic courtesy msnbc.com) is not new to cancer—in 1997 he beat prostate cancer following surgery. But as he admits, he hadn't seen his doctor since then.
"Yes, I know that’s stupid," he writes. "But it’s also the way it is. You can change it in your own life, and I recommend that you do. And I’ll deal with it in my life without beating myself up over things I can’t change."
He's getting ready to start chemotherapy on July 20, and has written two very readable (and highly informative) blog entries thus far. If interested, check them out.
Adventures in Cancerland, Part 1: The Diagnosis
Adventures in Cancerland, Part 2: Lust for Life
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
